<DOC>
	<DOCNO>NCT03028285</DOCNO>
	<brief_summary>Unifusol ( R ) solution arginine sodium succinate intravenous infusion . Its effect include vasodilation , protection inner layer blood vessel improvement blood viscosity . The present phase I study aim evaluate safety tolerability Unifusol infusion healthy volunteer .</brief_summary>
	<brief_title>Study Safety Tolerability UNIFUZOL ( Solution Infusions ) Healthy Volunteers</brief_title>
	<detailed_description>Unifuzol , solution infusion , ( `` NTFF POLYSAN '' Ltd. , Russia ) contain succinic acid arginine active ingredient ; demonstrate cardioprotective , anti-ischemic , endothelial protective fibrinolytic activity pre-clinical study consider clinical trial peripheral vascular disease . The primary aim present Phase I study assess safety tolerability Unifusol ( 1.4 % solution infusion ) different infusion rate healthy volunteer . Study objectives : 1 . Assess safety parameter ( vital sign , incidence AEs , SAEs , laboratory abnormality ) infusion Unifusol ( 1.4 % solution infusion ) healthy volunteer different infusion rate . - administration single infusion 250 ml rate 3 ml / min . - administration single infusion 250 ml rate 4.5 ml / min - administration single infusion 500 ml rate 4.5 ml / min 2 . Study pharmacokinetics parameter active component Unifusol ( succinic acid arginine ) healthy volunteer single infusion dose 250 ml rate 4.5 ml / min . Study method : 1 . Determination pharmacokinetic parameter succinic acid administer single Unifusol infusion dose 250 ml rate 4.5 ml / min ( AUC , Cmax , Tmax , T1 / 2 ) ; 2 . Determination pharmacokinetic parameter arginine single Unifusol infusion dose 250 ml rate 4.5 ml / min ( AUC , Cmax , Tmax , T1 / 2 ) ; 3 . Determination individual variation pharmacokinetic parameter succinic acid arginine healthy volunteer ; 4 . Identification significant gender difference pharmacokinetics active ingredient Unifusol ( succinic acid arginine ) healthy volunteer ; 5 . Determination number compartment pharmacokinetic model appropriate measure concentration single infusion ( single-chamber , two-chamber three-chamber pharmacokinetic model ) .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Healthy condition , verified standard clinical , laboratory instrumental method examination . 2 . The body mass index ( BMI ) 18.5 30 body weight 50 kg . 3 . Signed informed consent . 4 . For men consent use doublebarrier contraceptive method course study , 90 day study completion . 5 . For woman negative pregnancy test , absence lactation , consent use doublebarrier method contraception study 90 day study completion . In case hormonal contraceptive use , intake must cancel later 2 month start study . 1 . Intolerance hypersensitivity component study drug . 2 . Chronic disease cardiovascular , bronchopulmonary ( include bronchospastic disease ) , neuroendocrine system , chronic disease gastrointestinal tract , liver , kidney , blood , immune system , mental illness substance abuse , history alcoholism . 3 . Acute infectious disease within 4 week start study . 4 . Any abnormality laboratory finding inclusion . 5 . The presence mental disorder , history mental illness.\ 6 . Intake medication and/or nutritional supplement 14 day 5 halflives ( whichever longer ) prior first dose study drug , use drug significant effect hemodynamics , liver function , etc . ( instance , barbiturate , omeprazole , cimetidine ) 2 month prior first dose study medication . Receiving herbal medicine herbal supplement 28 day first dose study medication . 7 . Hormonal method contraception systemic effect ( include oral transdermal contraceptive , injectable progesterone , subcutaneous implant progestin intrauterine device progesterone release ) hormone replacement therapy within 60 day prior first dose study medication . 8 . The injection drug , depot ( slow release ) use drug implant within 3 month prior administration study drug . 9 . Abnormalities vital sign : systolic blood pressure 100 mm Hg high 130 mm Hg ; diastolic blood pressure 60 mmHg 90 mm Hg ; heart rate 60 beat / min 90 beat / min . 10 . Data 12lead ECG demonstrate QTc interval &gt; 450 msec QRS &gt; 120 m screen visit . 11 . Blood donation ( 450 ml blood ) less 3 month prior inclusion . 12 . Participation clinical trial drug 3 month inclusion . 13 . The regular consumption 5 unit alcohol per week ( unit equal 30 ml ethanol 325 ml beer ) history alcoholism , drug addiction , drug abuse . 14 . A positive test alcohol exhale air . 15 . Smoking 10 cigarette per day . 16 . A positive urine test drug , amphetamine , marijuana , morphine , cocaine methamphetamine , tricyclic antidepressant , reveal urine immunoassay analysis . 17 . The positive result analyze hepatitis B C , HIV , and/or syphilis . 18 . Unwilling unable give alcohol intake , smoke excessive exercise 48 hour prior study drug administration 96 hour administration drug , well food beverage contain methylxanthines grapefruit / grapefruit juice day prior screen visit followup . 19 . Compliance special diet ( eg . vegetarian ) lifestyle ( include night work extreme exercise , sport weight lift ) may interfere study procedure . 20 . Planning inpatient treatment volunteer within one month first injection study drug . 21 . Lack intention comply study regimen . 22 . Obvious probable inability volunteer , accord judgement researcher , understand evaluate information study consciously sign informed consent form , particular respect expect risk possible discomfort . 23 . Expected problem placement venous catheter perform vein puncture . 24 . Pregnancy breastfeeding ; unwillingness inability woman childbearing age use acceptable method barrier contraception , accord protocol , start least 14 day prior first dose study medication 90 day study completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>succinate</keyword>
	<keyword>arginine</keyword>
	<keyword>vasodilation</keyword>
	<keyword>peripheral vascular disease</keyword>
</DOC>